The extracellular sulfatases Sulf1 and Sulf2 remodel the 6-O-sulfation state of heparan sulfate proteoglycans on the cell surface, thereby modulating growth factor signaling. Different from all other sulfatases, the Sulfs contain a unique, positively charged hydrophilic domain (HD) of about 320 amino acid residues. Using various HD deletion mutants and glutathione S-transferase (GST)-HD fusion proteins, this study demonstrates that the HD is required for enzymatic activity and acts as a high affinity heparin/heparan sulfate interaction domain. Association of the HD with the cell surface is sensitive to heparinase treatment, underlining specificity toward heparan sulfate chains. Correspondingly, isolated GST-HD binds strongly to both heparin and heparan sulfate in vitro and also to living cells. Surface plasmon resonance studies indicate nanomolar affinity of GST-HD toward immobilized heparin. The comparison of different mutants reveals that especially the outer regions of the HD mediate heparan sulfate binding, probably involving “tandem” interactions. Interestingly, binding to heparan sulfate depends on the presence of 6-O-sulfate substrate groups, suggesting that substrate turnover facilitates release of the enzyme from its substrate. Deletion of the inner, less conserved region of the HD drastically increases Sulf1 secretion without affecting enzymatic activity or substrate specificity, thus providing a tool for the in vitro modulation of HS-dependent signaling as demonstrated here for the signal transduction of fibroblast growth factor 2. Taken together, the present study shows that specific regions of the HD influence different aspects of HS binding, cellular localization, and enzyme function.

The human sulfatases represent a family of 17 enzymes responsible for the turnover and remodeling of sulfate esters and sulfamates. Their reaction mechanism relies on a special amino acid residue, Cα-formylglycine, which is generated post-translationally via oxidation of a conserved cysteine residue in the active site (1–3). Besides the lysosomal sulfatases involved in the cellular degradation of various sulfated substrates (4), two extracellular sulfatases, Sulf1 and Sulf2 (the Sulfs), have been described (5, 6). The Sulfs are endosulfatases with restricted substrate specificity toward 6-O-sulfate groups of heparan sulfate (HS), an information-rich glycosaminoglycan (GAG) polymer attached to proteoglycans at the cell surface and in the extracellular matrix (6–8). HS proteoglycans (HSPGs) act as co-receptors in cell signaling pathways and provide binding sites for growth factors and morphogens via specific sulfation patterns on their HS chains. By enzymatically removing 6-O-sulfate groups from HSPGs on the cell surface, Sulf1 and Sulf2 differentially regulate the activity of FGF, vascular endothelial growth factor, Wnt, and other HS ligands, thereby modulating important processes such as development, cell growth, and differentiation (9–12). Misregulation of the Sulfs has been linked with both tumor progression and suppression, depending on either activating or inhibitory effects upon cell signaling (13–16).

To investigate the physiological role of Sulf1 and Sulf2, single and double knock-out mice were generated (17–21). Both Sulf1 and Sulf2 knock-out mice are characterized by increased embryonic lethality, impaired neurite outgrowth, and other neurological abnormalities in the developing and adult nervous system (22). The corresponding double knock-out mice display an obvious reduction in body weight and developmental malformations, including skeletal and renal defects (18, 19, 23). Together with biochemical analyses on the impact of Sulf loss on HS sulfation, the phenotypic observations suggest a functional cooperativity between Sulf1 and Sulf2 in modulating the 6-O-sulfation of UA(2S)-GlcNS(6S) disaccharide units within the S-domains of HS chains (17, 24). Moreover, analyses of heparan sulfate disaccharide compositions from Sulf1 and Sulf2 knock-out mice cell lines have indicated dynamic influences of Sulf loss also on non-substrate N-, 2O-, and 6-O-sulfate groups via modulation of sulfotransferase expression, which may contribute to the developmental defects associated with the Sulf knock-out mice (24).

From the biochemical perspective, it is an important question how the Sulfs are able to recognize their HSPG substrates and how cell surface localization is achieved, despite a lack of transmembrane domains or lipid anchors. Classical GAG-binding proteins, such as antithrombin III (25) or FGF1 (26), interact with their negatively charged GAG partners via small clusters of positively charged amino acid residues. Although

2 The abbreviations used are: HS, heparan sulfate; FGF, fibroblast growth factor; GlcNAc, N-acetylglucosamine; GlcNS, N-sulfoglucosamine; GST, glutathione S-transferase; HPLC, high performance liquid chromatography; HSPG, heparan sulfate proteoglycan; NS, N-sulfate; 2S, 2-O-sulfate; 6S, 6-O-sulfate; UA, hexuronic acid; GAG, glycosaminoglycan; MEF, mouse embryonic fibroblasts; 4-MUS, 4-methylumbelliferyl sulfate; HD, hydrophilic domain; PBS, phosphate-buffered saline; FACS, fluorescence-activated cell sorter; ERK, extracellular signal-regulated kinase.
some consensus sequences for heparin binding have been identified (XBBXBX, XBBXXBXX, and XBBXXBBBXBBX, where B is a basic residue and X a hydrophobic) (27–29), they are neither required nor sufficient. Unlike these classical GAG-binding proteins, Sulf1 and Sulf2 contain a large hydrophilic domain (HD), located between the N-terminal catalytic domain and the C-terminal domain. The HD is a unique feature of the extracellular sulfatases that is neither found in other sulfatases nor shows any homology with other known protein domains. According to sequence alignments, the HD of human Sulf1 has a size of ~320 amino acid residues, 27% of which are basic and 14% acidic, resulting in a strong positive charge at neutral pH and a high theoretical pI of 9.8. Remarkably, the C-terminal end of the HD is composed of a cluster of 12 basic amino acid residues. Whereas the outer regions of the HD are highly conserved between Sulf1 and Sulf2 as well as between human, murine, and avian orthologs, the inner region, encoded by exons 13 and 14 in the case of human Sulf1 (6), is significantly less conserved.

The role of the HD has previously been investigated for the avian ortholog QSulf2 (30). Results from this study indicated that the HD binds to negatively charged ligands and might serve to anchor the enzyme on the cell surface. Sulfate release assays indicated the necessity of the avian HD for enzymatic activity. Moreover, a very recent analysis of the HD of human Sulf1/Sulf2 revealed the presence of two furin-type proteinase cleavage sites within the inner region, explaining their partial processing of the enzyme. Sulfate release assays indicated the necessity of the avian HD for enzymatic activity.

Due to the observed differences in enzyme secretion and detergent solubility between the human and avian orthologs (24, 30) and the likely importance of this domain for mammalian Sulf localization and activity, we analyzed the function of the HD of human Sulf1 in mediating enzyme activity, cell surface targeting, secretion, and substrate recognition. Using different Sulf1 deletion mutants and glutathione S-transferase (GST)-HD fusion proteins, this study demonstrates that specific regions of the HD, especially at the conserved N and C termini, are responsible for heparin/HS binding, cell surface localization, and enzymatic activity of human Sulf1. Interaction analyses show that binding of the HD to heparin is significantly stronger compared with other typical heparin-binding proteins, suggesting a new mode of GAG binding. The deletion of the inner region of the HD leads to significantly increased secretion of the enzyme, allowing the purification of an active variant that is able to modulate FGF signaling in cell culture experiments.

**EXPERIMENTAL PROCEDURES**

**Construction of Expression Plasmids**—The human full-length Sulf1 cDNA sequence was cloned into the pcI-neo expression vector (Promega) and equipped with a C-terminal RGS-His₆ tag as described (24). The deletion mutants Sulf1ΔHD (ΔK417–K735), Sulf1ΔHDB (ΔK417–N720), and Sulf1ΔHDC (ΔQ459–H616) were generated by site-directed mutagenesis according to the QuikChange protocol (Stratagene, for primer sequences see supplemental Table S1). The preparation of the enzymatically inactive Sulf1 C87A/C88A mutant (Sulf1 CA) and cloning of human full-length Sulf2 cDNA have previously been described (24). For heterologous expression of the isolated HD of Sulf1 in *Escherichia coli*, cDNA fragments encoding Sulf1ΔHD (residues Lys417–Lys735), Sulf1HDB (residues Lys417–Asn720), and Sulf1HDC (residues Lys417–Lys735, ΔQ459–H616) were amplified by PCR using Sulf1 or Sulf1ΔHDC as a template and cloned via Nhel/Xhol restriction sites into pET21b+ (Novagen). To the coding sequences, an N-terminal TEV-cleavable RGS-His₆ tag and a C-terminal Strep tag II were added (for primer sequences see supplemental Table S2). Due to the formation of inclusion bodies upon expression in *E. coli*, the constructs were subcloned into pKM263 (32) via Xhol/BamHI sites, thereby obtaining the corresponding N-terminal GST fusion constructs, GST-HD, GST-HDB, and GST-HDC (for primer sequences see supplemental Table S2). For surface plasmon resonance experiments with streptavidin biosensor chips, corresponding constructs without the C-terminal Strep tag II were prepared (supplemental Table S2). All plasmid constructs were sequenced in the coding region to preclude any PCR-derived errors.

**Cell Culture and Transfection**—HT1080 human fibrosarcoma cells were grown and transfected as previously described (24). Stable clones were screened for protein expression by Western blot analysis of cell lysates and cell culture supernatants, using a mouse monoclonal antibody directed against the RGS-His₆ epitope (Qiagen) as described (24, 33).

**Protein Purification**—Cell culture supernatants from HT1080 cells stably overexpressing Sulf1ΔHDC were collected and enriched by Ni²⁺ affinity chromatography as previously described for human arylsulfatase G (33). Sulf1ΔHDC eluted at a concentration of ~150–200 mM imidazole. Peak fractions, as analyzed by Western blotting and 4-methylumbelliferyl sulfate (4-MUS) assays were pooled. Protein concentrations were determined by Western blotting using purified, RGS-His₆-tagged formylglycine-generating enzyme as a standard (34).

For purification of GST fusion proteins, expression plasmids were transformed into *E. coli* BL21(DE3) cells. Cells were grown in LB medium at 37 °C to an A₆₀₀ of 0.5 and induced with isopropyl 1-thio-β-d-galactopyranoside at a final concentration of 0.1 mM. Proteins were expressed at 30 °C for 2 h. The cells were harvested by centrifugation and lysed in lysis buffer (1 mM EDTA, 1% Triton X-100 in PBS, pH 7.3) using a French press. GST fusion proteins were purified from the soluble fraction by affinity chromatography on a GSTrap HP 1-mL column (GE Healthcare). After washing with PBS, proteins were eluted with elution buffer (50 mM Tris, 10 mM reduced glutathione, pH 8.0). Peak fractions, as determined by SDS-PAGE/Coomassie staining and Western blotting with a polyclonal goat anti-GST antibody (GE Healthcare), were pooled and loaded onto a HiTrap heparin HP 1-mL column (GE Healthcare). After washing with binding buffer (20 mM Tris, pH 7.4), proteins were gradually eluted with elution buffer (20 mM Tris, 1.5 M NaCl, pH 7.4). Peak fractions were subsequently desalted on a HiTrap Desalt 5-ml column (GE Healthcare) using PBS as running buffer. Protein concentrations were determined using Coomassie Plus Bradford reagent (Pierce). Average yields of soluble

---

**The Hydrophilic Domain of Human Sulf1**

---

---
proteins were about 50 or 25 μg/liter LB medium for GST-HD or GST-HDB and GST-HDC, respectively.

In Vitro Sulf Activity Assays—Activities of Sulf1 and Sulf1 mutants toward the fluorogenic pseudosubstrate 4-MUS were determined by incubating cell lysates with 2 mM 4-MUS in 10 mM HEPES (pH 7.4) for 1 h at 37 °C. Reactions were analyzed as previously described (33). Endosulfatase activities toward HS were investigated using [3H]glucosamine-labeled HS isolated from Sulf1/Sulf2 double knock-out mouse embryonic fibroblasts as a substrate (24). Assays were performed with either cellular or secreted Suls, purified from cell lysates on nickel-Sepharose beads (GE Healthcare) or enriched from conditioned medium, respectively (24). In the case of purified Sulf1ΔHDC, unlabeled HS or heparin from porcine intestinal mucosa (from Celsus Laboratories or Sigma, respectively) was used as substrates. Therefore, 1 mg of HS or heparin was incubated with Sulf1ΔHDC at a final substrate concentration of 1 mg/ml for 1 h at 37 °C and pH 7.4. Samples were digested to disaccharides and resolved by strong anion exchange HPLC as described (24). Disaccharide peaks were identified from UV absorbance of the Δ4,5 bond at 232 nm. Experiments with chondroitin sulfate B (Sigma) were performed accordingly, using chondroitinase ABC (Sigma) for disaccharide composition analysis.

Preparation of HS Affinity Columns—HS from porcine intestinal mucosa (Celsus) or HS material 60-oligosulfated by Sulf1ΔHDC (see above) were desalted on PD10 columns, freeze-dried, and reductively aminated at the reducing terminus based on a previously published protocol (35). Briefly, 50 mg of GAG material in 2 ml of 2 M NH4Cl was incubated with 100 mg of NaCNBH3 for 2 days at 60 °C. A further 50 mg of NaCNBH3 was added and incubated for an additional 3 days at 60 °C. After desalting, GAGs were coupled to HiTrap NHS 1-ml columns (GE Healthcare) at a concentration of 10 mg/ml in coupling buffer (0.2 M NaHCO3, pH 8.3) overnight at 4 °C. Unreacted NHS was quenched with 0.5 M ethanolamine (pH 8.3). As a control, a reference column without GAGs but inactivated with ethanolamine was generated. GST-HD was applied to the columns and gradually eluted with NaCl as described above.

BaSO4 Assay—Release of inorganic sulfate from HS or heparin was quantified via a BaSO4 precipitation assay adapted from Lundquist et al. (36). In brief, 200 μl of each sample were mixed with 100 μl of Ba2+ reagent (40 mM BaCl2, 7.5% (w/v) polyethylene glycol 6000, 60 μM K2SO4). After a 5-min incubation at room temperature, turbidimetry was measured at 600 nm using a TECAN infinite M200 microplate reader (TECAN, Crailsheim, Germany) and compared with a standard curve with K2SO4 from 5 to 250 μM.

Immunofluorescence Microscopy—The cell surface localization of Sulf1 and the Sulf1 deletion mutants, overexpressed in HT1080 cells, was analyzed by immunofluorescence microscopy as previously described (24). Binding of GST-HD to the cell surface of untransfected HT1080 cells was assayed by incubating the cells with purified protein at a final concentration of 20 ng/μl for 1 h at 37 °C. Purified GST was used as a control for unspecific binding. The cells were washed with PBS and labeled with polyclonal goat anti-GST antibodies (GE Healthcare) for 1 h at 4 °C. After fixation and blocking, cells were incubated with Alexa 546-conjugated donkey anti-goat IgG secondary antibodies and processed as above.

FACS Experiments—To assay the binding of GST-HD to the cell surface, untransfected HT1080 cells were grown to subconfluence, harvested with a cell scraper, and incubated with purified GST-HD, GST-HDB, or GST-HDC fusion proteins for 1 h at 4 °C at a final concentration of 1.5 μM (100 ng/μl) in PBS. Purified GST (1.5 μM, 40 ng/μl) and PBS were used as negative controls. The cells were washed three times with PBS and incubated with polyclonal goat anti-GST antibodies (GE Healthcare) for 1 h at 4 °C in Dulbecco’s modified Eagle’s medium. After washing three times with PBS, primary antibodies were detected with Alexa 546-conjugated donkey anti-goat IgG secondary antibodies in Dulbecco’s modified Eagle’s medium, 1% fetal calf serum. Again, the cells were washed, resuspended in HEPES buffer (10 mM HEPES, 150 mM NaCl, pH 7.4), and analyzed using a FACS calibur system (BD Biosciences). To determine binding specificity, cells were treated with either trypsin or heparinases II and III from Flavobacterium heparinum prior to incubation with GST fusion proteins. Therefore, the cells were incubated with 2 ml of 0.05% trypsin/EDTA (Invitrogen) for 10 min at 37 °C or with 2 μl of each heparinase II and III (IBEX) in Dulbecco’s modified Eagle’s medium for 1 h at 37 °C. In both cases, the cells were extensively washed with PBS, incubated with GST-HD as described above, and exposed to primary and secondary antibodies for subsequent FACS analysis.

Heparan Sulfate Binding Assay—30 μmol of GST-HD, GST-HDB, or GST-HDC fusion proteins in PBS were immobilized on 100 μl of glutathione-agarose beads (Sigma). The beads were incubated with 50,000 cpm of [3H]labeled HS from Sulf1/2 double-deficient mouse embryonic fibroblasts (24) in 500 μl of PBS for 1 h at room temperature and washed three times with 500 μl of PBS to remove unspecifically bound HS. Specifically bound HS was eluted with 500 μl of 2 M NaCl after incubation for 10 min at room temperature with gentle agitation. The amount of [3H]HS in the wash and elution fractions was quantified via liquid scintillation counting.

FGF Signaling Assay—Growth factor signaling experiments were performed as previously described using wild type and Sulf1/Sulf2 double knock-out mouse embryonic fibroblasts (24). Prior to addition of FGF2, the cells were treated for 1 h at 37 °C with purified Sulf1ΔHDC in serum-free medium at a final concentration of 1.5 μg/ml. As a negative control, binding buffer with 270 mM imidazole was used instead of Sulf1ΔHDC. Subsequently, cells were washed twice with PBS and incubated with 1 ng/ml FGF2 for 10 min at 25 °C. Equal protein amounts of cell lysates were analyzed for diphospho and non-phosphorylated ERK1/2 signal intensities on Western blots and quantified as previously described (37).

Surface Plasmon Resonance—Biotinylated heparin (from porcine intestinal mucosa, average molecular mass 15 kDa, Merck) was immobilized (~100 response units) on the surface of a Biacore sensor chip SA (GE Healthcare) according to the manufacturer’s instructions using a Biacore 3000 system. Flow cell 1 served as a reference without immobilized heparin. PBS (pH 7.3) was used as running buffer for all experiments at a flow rate of 30 μl/min. Different concentrations of GST-HD without the C-terminal Strep tag II (125 to 1000 nM in PBS) were
injected onto the chip surface and proteins were allowed to associate for 3 min, followed by a dissociation phase of 15 min. The sensor surface was regenerated by two short pulses (20 s) of 0.05% SDS with subsequent stabilization for 30 min.

RESULTS

Generation and Characterization of Sulf1 Deletion Mutants—To investigate the functional importance of the HD of human Sulf1, we generated HT1080 cell lines stably overexpressing Sulf1 mutants in which the HD was either partially or completely deleted (Fig. 1A). In the first mutant, Sulf1ΔHD, the entire HD (K417-K735) was removed. In contrast, the basic cluster at the C-terminal end of the HD was not deleted in the second mutant, referred to as Sulf1ΔHDB (K417-N720). A third mutant, Sulf1ΔHDC, was prepared, containing only the evolutionary conserved outer regions of the HD but lacking the divergent inner region, encoded by exons 13 and 14 (Q459-H616).

Based on its amino acid sequence, a molecular mass of 100 kDa was expected for the RGS-His6-tagged full-length Sulf1 protein after signal peptide cleavage (residues 1–22). Sizes of 62, 64, and 82 kDa were anticipated for Sulf1ΔHD, -ΔHDB, and -ΔHDC, respectively. Analysis of cell lysates of stably transfected HT1080 cell lines was analyzed by Western blotting using a mouse anti-RGS-His6 antibody. As a negative control, untransfected cells (UT) were used (B). Accordingly, secretion into the conditioned medium was analyzed in 100-fold concentrated medium samples and compared with Sulf2 (C). Furthermore, cell lysate samples from the HT1080 cell lines were subjected to deglycosylation with peptide-N-glycosidase F (PNGase F) and analyzed by Western blotting (D).

FIGURE 1. Expression, secretion, and glycosylation of Sulf1 and Sulf1 mutants. Full-length Sulf1 is composed of a signal peptide (SP), the catalytic domain (CD), the hydrophilic domain (HD), and a C-terminal domain (CT). The C-terminal end of the HD contains a highly basic cluster, represented by a white bar. Sulf1 CA (lacking the active site Ca-formylglycine (FGly) residue) and the three deletion mutants of Sulf1 were generated as described in the text. As a complementary approach, GST fusion proteins containing different regions of the HD were prepared for production in E. coli (A). The expression of Sulf1 and Sulf1 mutants in cell lysates of stably transfected HT1080 cell lines was analyzed by Western blotting using a mouse anti-RGS-His6 antibody. As a negative control, untransfected cells (UT) were used (B). Accordingly, secretion into the conditioned medium was analyzed in 100-fold concentrated medium samples and compared with Sulf2 (C). Furthermore, cell lysate samples from the HT1080 cell lines were subjected to deglycosylation with peptide-N-glycosidase F (PNGase F) and analyzed by Western blotting (D).
nal fragments of ~40 and 45 kDa. In the case of deletion mutants Sulf1ΔHD, Sulf1ΔHDB, and Sulf1ΔHDC, less processing was observed, corresponding to recent findings that furin-type proteinase processing occurs at two cleavage sites within the inner region of the HD (31). Interestingly, deletion of the HD or parts thereof significantly promotes secretion of the enzyme as reflected by increased amounts of the mutants in the conditioned medium (Fig. 1C). The most dramatic increase in secretion was observed for deletion mutant Sulf1ΔHDC which, compared with the full-length Sulf1, revealed about 30–50-fold higher abundance in the conditioned medium. These findings correspond in part to the increased cellular expression levels (Fig. 1B). On the other hand, the strong increase in secretion also suggested a role of the HD in interactions with the cell surface.

**Deletion of the HD Does Not Alter Protein Glycosylation**—The sequence of human Sulf1 contains 10 potential N-glycosylation sites (positions 64, 111, 131, 148, 170, 197, 240, 623, 773, and 783) but no predicted positions for O-glycosylation or sialylation. One of the potential N-glycosylation sites is located within the HD (position 623). In the case of the quail ortholog, QSulf1, two N-glycosylation sites are predicted in the HD (positions 527 and 620). A systematic analysis of the N-glycosylation of QSulf1 has revealed that neither of these two sites are utilized *in vivo* (38). Furthermore, protein N-glycosylation was shown to be essential for enzymatic activity and membrane targeting of QSulf1. To exclude that deletion of the HD of human Sulf1 affects N-glycosylation of the mutants, lysates from Sulf1 and Sulf1 mutant expressing cells were subjected to treatment with peptide-N-glycanase F to release all N-linked glycan structures (Fig. 1D). Removal of N-glycans resulted in protein bands close to the calculated sizes without signal peptide (104, 61, 65, and 81 kDa for Sulf1, Sulf1ΔHD, -ΔHDB, and -ΔHDC, respectively). In accordance with full-length Sulf1, the observed shift in electrophoretic mobility was ~15 kDa for all proteins, suggesting that deletion of the HD does not lead to major differences in protein glycosylation and confirming that the HD itself is not glycosylated.

**In Vitro Activity of HD Deletion Mutants**—To compare the enzymatic activities and specificities of full-length Sulf1 and the three HD deletion mutants toward their physiological substrate, we used an *in vitro* activity assay based on [3H]glucosamine-labeled heparan sulfate as a substrate. Isolated from Sulf1/2 double-deficient mouse embryonic fibroblasts (24). Because this HS material has not been exposed to endogenous Sulf activity, maximum sensitivity is provided by a high degree of physiological 6-O-sulfation.

Lysates of transfected cells, expressing full-length Sulf1, inactive Sulf1 CA, Sulf1ΔHD, ΔHDB, or ΔHDC mutants were partially purified on nickel-Sepharose beads and normalized protein amounts were incubated with 3H-labeled HS. Following depolymerization, the corresponding disaccharides were resolved by strong anion exchange HPLC (Fig. 2A). Furthermore, the activities of the secreted Sulfs were analyzed from conditioned medium samples (Fig. 2B).

Importantly, deletion of the HD or parts thereof led to a differential loss of enzymatic activity. In the case of proteins purified from cell lysates, incubation of HS chains with full-length Sulf1 resulted in a ~50% reduction of the trisulfated UA(2S)-GlcNS(6S) disaccharide and a concomitant increase of the corresponding disulfated UA(2S)-GlcNS unit (Fig. 2A). The amount of disulfated UA-GlcNS(6S) was reduced by ~20%. No
activity toward the transition zone-associated disaccharide unit UA-GlcNAc(6S) was detected. Negative controls with cell lysates from untransfected cells and inactive Sulf1 CA expressing cells indicated no background activity compared with untreated HS. Among the three deletion mutants, only Sulf1ΔHDC had significant activity, resulting in a ~35% reduction of UA(2S)-GlcNS(6S). Disulfated UA-GlcNS(6S) was reduced by only 15%. Sulf1ΔHD and Sulf1ΔHDB were inactive toward all detectable disaccharide units within the HS chains.

Compared with intracellular Sulf activities, assays with secreted Sulfs from the conditioned medium showed endosulfatase activities not only for Sulf1 and Sulf1ΔHDC but also for Sulf1ΔHDB (Fig. 2B). In accordance with cell lysate results, no activity could be detected for Sulf1ΔHD. In the case of full-length Sulf1, the amount of trisulfated UA(2S)-GlcNS(6S) was reduced by ~80%. Sulf1ΔHDC had even higher activity with ~90% reduction, probably also due to better secretion of the enzyme as described above. It should be noted that due to the low secretion of full-length Sulf1, a reliable normalization of protein concentrations from the conditioned medium was not possible. Treatment of HS with secreted Sulf1ΔHDB resulted in a ~50% reduction of the trisulfated UA(2S)-GlcNS(6S) disaccharide. The inactivity of Sulf1ΔHDB in the cell lysate samples might be explained by a high degree of misfolding of the intracellular protein. Activity trends toward the disulfated UA-GlcNS(6S) unit were similar to those observed toward the trisulfated UA(2S)-GlcNS(6S) species with 25, 35, 10, or 0% reduction upon incubation with full-length Sulf1, Sulf1ΔHDC, Sulf1ΔHDB, or Sulf1ΔHD, respectively. As observed for full-length Sulf1, none of the mutants were active toward monosulfated UA-GlcNAc(6S) disaccharide units (Fig. 2, A and B). Furthermore, no activity against N- or O-sulfate moieties or toward chondroitin sulfate/dermatan sulfate was observed for any Sulf variant (data not shown). Taken together, these findings confirm that deletion of parts of the HD in the case of Sulf1ΔHDC and ΔHDB does not alter the substrate specificity of Sulf1 within HS chains. A deletion of the entire HD leads to a complete loss of enzymatic activity toward the physiological substrate.

To determine whether this loss of activity is a result of protein misfolding or reduced substrate affinity, the small fluorogenic pseudosubstrate 4-MUS was used as an alternative substrate in enzyme assays based on normalized cell lysates (Fig. 2C). No differences in activities were detected between full-length Sulf1 and Sulf1ΔHDC, whereas ΔHDB had only about 50% activity. Interestingly, Sulf1ΔHD, which is inactive toward HS, had about 30% activity against 4-MUS, suggesting a role of the HD and especially the basic cluster at its C-terminal end in directing substrate specificity.

**Biochemical Characterization of Sulf1ΔHDC**—Biochemical analysis of the Sulfs has been complicated by the poor secretion of the enzymes in eukaryotic expression systems, reported by us and other groups (6, 24, 30), and fragmentation upon expression in E. coli (data not shown). Due to the high activity in vitro and significantly enhanced secretion compared with full-length Sulf1, the Sulf1ΔHDC mutant opened up the possibility for production and purification at a larger scale, allowing a detailed enzymatic characterization. Therefore, conditioned medium from stably transfected HT1080 cells was partially purified by Ni^{2+} affinity chromatography. This approach enabled acquisition of ~10 μg of Sulf1ΔHDC per liter of cell culture medium, as determined by Western blot analysis. To find optimal conditions for 4-MUS hydrolysis, we analyzed the pH and temperature dependence of the reaction and found a broad pH optimum between pH 5.5 and 7.5 with a peak at 6.6 (Fig. 3A). At pH 8, Sulf1ΔHDC has only 25% residual activity, whereas full-length Sulf1, according to previous reports, has comparable activities at pH 7 and 8 (6). During incubation for 1 h, Sulf1ΔHDC cleaved 4-MUS most efficiently at ~35 °C and rapidly lost activity at higher temperatures (Fig. 3B). At 37 °C, the turnover of 4-MUS is stable for about 2 h, whereas no further activity was observed after 8 h (Fig. 3C). According to substrate dose-response curves (Fig. 3D), Sulf1ΔHDC cleaves 4-MUS with a specific activity \( V_{\text{max}} \) of 2400 nmol/(min/mg). This result is similar to the activity that was previously estimated for full-length Sulf1 (1000–2000 nmol/(min/mg)) (6). The affinity of Sulf1ΔHDC toward the artificial substrate 4-MUS is rather low, as indicated by an estimated \( K_m \) value of 15 mM. In addition to
4-MUS, para-nitrocatechol sulfate was also found to be cleaved by Sulf1ΔHDC, albeit with very low activity of ~0.05 nmol/(min/mg).

Similar to many other sulfatases such as arylsulfatase G (33), the activity of Sulf1ΔHDC is inhibited by inorganic phosphate (Fig. 3E). The calculated IC<sub>50</sub> value is about 1 mM. At concentrations <3 mM, inorganic sulfate also has an increasingly inhibitory effect on 4-MUS cleavage (Fig. 3F). Surprisingly, concentrations above ~3 mM result in a strong activation of the enzyme. At a concentration of 30 mM sulfate, the reaction was accelerated almost 10-fold compared with a control without sulfate addition. In experiments where HS was used as a substrate, the addition of sulfate did not result in increased activity but in weak inhibition (data not shown), suggesting that the activating effect is restricted to the turnover of the pseudosubstrate.

Although the experiments with endogenous HS material as a substrate enabled a comparison of the Sulf1 deletion mutants (Fig. 2, A and B), the unknown chemical amounts of substrate used in this radioactive assay precluded further quantitative or kinetic analyses. Therefore, partially purified Sulf1ΔHDC was incubated with defined amounts of unlabeled heparin. Heparin was tested as a substrate due to its structural similarity to the highly sulfated S-domains found in endogenous HS. As shown in Fig. 4A, the trisulfated UA(2S)-GlcNS(6S), representing the major disaccharide repeat unit of heparin, was reduced by 85% upon incubation of 1 mg of heparin with 0.7 μg of Sulf1ΔHDC. The disulfated UA-GlcNS(6S) unit was reduced by 20%, whereas no activity was observed toward other disaccharide units within the heparin chains. Using repeated enzyme treatments, preparative amounts of 20 mg of HS were also specifically 6O-desulfated by Sulf1ΔHDC to the same extent, thereby providing an important tool for further functional studies.

To directly compare the kinetics of the desulfation of heparan sulfate by Sulf1ΔHDC, the amount of released sulfate at different substrate concentrations was analyzed by precipitation with Ba<sup>2+</sup> and turbidimetric quantification. This assay allowed, for the first time, characterization of Sulf1 enzyme kinetics toward its endogenous substrates. As shown in Fig. 4B, increasing concentrations of substrate resulted in a hyperbolic curve shape with substrate saturation at concentrations of ~1 mg/ml for both heparin and heparan sulfate. The highest activities were observed for heparin, probably due to the increased amount of trisulfated UA(2S)-GlcNS(6S) substrate units. Indeed, because heparin lacks the varied domain structure of endogenous heparan sulfate, it is also conceivable that the turnover of heparin by Sulf1ΔHDC is characterized by a higher processivity without dissociation of the enzyme from the GAG chain. The kinetic parameters V<sub>max</sub> and K<sub>m</sub> were determined from the corresponding direct-linear plots (39) (Fig. 4, D and E). In the case of heparin, a V<sub>max</sub> of 6200 nmol/(min/mg) and a K<sub>m</sub> of ~13 μg/ml were estimated from the intersection of the lines. HS was desulfated with V<sub>max</sub> = 5100 nmol/(min/mg) and K<sub>m</sub> ~5 μg/ml. Both activities are significantly lower compared with the artificial substrate 4-MUS (V<sub>max</sub> = 2400 nmol/(min/mg), see above). Furthermore, the difference in K<sub>m</sub> values suggests that Sulf1ΔHDC has an increased affinity toward HS, the physiologically relevant substrate, and might have a preference toward the domain structure of HS.

To further investigate the substrate preference of Sulf1ΔHDC, assays with the artificial substrate 4-MUS were performed in the presence of different concentrations of heparan sulfate as a competitor (Fig. 4C). Already at low concentrations, HS represents the preferred substrate of Sulf1ΔHDC. A concentration of 230 ng/ml of HS (~5 nm assuming an average HS chain length of 100 disaccharides) is sufficient to reduce the hydrolysis of 10 μM 4-MUS in the substrate mixture by 50%. Similar competition efficiencies were observed in the case of 6O-desulfated HS as a competitor. This finding might suggest that binding of the HS substrate blocks the entry of 4-MUS to the active site.

**Sulf1ΔHDC Modulates FGF Signaling ex Vivo**—To investigate whether partially purified Sulf1ΔHDC is also active toward HSPGs on the cell surface, the effect of Sulf1ΔHDC on FGF signaling was analyzed in an *ex vivo* experiment. As previously reported (24), mouse embryonic fibroblasts (MEFs) isolated...
from Sulf1/Sulf2 double-deficient mice were characterized by a strong increase in HSPG 6-O-sulfation. The presence of 6-O-sulfate groups leads to an increased signaling response upon stimulation with the heparan sulfate-dependent growth factor FGF2 as compared with wild type MEFs. Preincubation of these cells with Sulf1ΔHDC significantly reduced the FGF signaling response, as measured by the ratio of phosphorylated ERK relative to the amount of total ERK (A). Non-induced controls were set to 100% and compared with the FGF2-induced cells. Treatment of the cells with Sulf1ΔHDC reduces the FGF signaling response to a level slightly above the wild type controls (B). Error bars represent S.D. from three independent experiments.

**The Isolated HD of Sulf1 Interacts with Heparin/HS Depending on 6-O-Sulfate Substrate Groups**—In addition to the Sulf1 deletion mutants, the isolated HD of Sulf1 was analyzed. Based on glycosylation analysis of human Sulf1 (see above) and previous results from the quail ortholog Qsulf1 (38), the absence of glycan structures within the HD enables heterologous expression of the isolated HD in *E. coli*. Therefore, N-terminal GST fusion constructs GST-HD, GST-HDB, and GST-HDC were generated, containing either the entire HD of human Sulf1 or fusion constructs GST-HD, GST-HDB, and GST-HDC eluted at 1050, 950, and 1100 mM, respectively, whereas GST alone eluted at 130 mM NaCl (Fig. 6B). The same system has previously been used to classify heparin interactions of other typical heparin-binding proteins (40) (see “Discussion”).

To investigate the interaction with the physiological substrate HS, binding experiments were carried out using 3H-labeled HS isolated from Sulf1/Sulf2 double knock-out MEFs (24). To quantify the degree of binding, normalized amounts of GST fusion proteins were immobilized on glutathione-agarose and incubated with HS. After stringent washing, the specifically bound radiolabeled HS was eluted from the bead-bound GST fusion proteins with 2 M NaCl and quantified via scintillation counting (Fig. 6C). A significant amount of radioactivity was found in the elution fractions of GST-HD, GST-HDB, and GST-HDC but not in the eluates of beads loaded with GST alone or beads without any protein, both of which served as negative controls. Interestingly, whereas GST-HD and GST-HDB showed comparable binding of HS, about 8-fold increased retention was found in the case of GST-HDC, reflecting the elution order also observed in heparin affinity chromatography. Furthermore, we investigated the specific role of 6-O-sulfate substrate groups in HS binding. To this end, commercial HS was treated with Sulf1ΔHDC as described above, yielding about 75% reduction in 6-O-sulfation. The material was reductively aminated at the reducing end and immobilized on NHS-activated Sepharose beads to obtain an affinity column with specifically 6-O-desulfated HS ligands. Whereas GST-HD eluted at a concentration of about 850 mM NaCl from control columns conjugated with the same amount of untreated HS, almost no specific interaction was detected on columns with HS that had been treated with Sulf1ΔHDC (Fig. 6D). Indeed, about 95% of GST-HD loaded onto this column was found in the flow-through fraction (data not shown), suggesting a pivotal role of 6-O-sulfate groups in HD binding and release.

**The HD Is Required for Targeting of Sulf1 to the Cell Surface**—To determine whether heparin/heparan sulfate binding of the HD plays a role in targeting Sulf1 to the cell surface, we analyzed the effect of HD deletion on membrane targeting. Imaging of cells transfected with the Sulf1 deletion mutants in immunofluorescence microscopy revealed a clear cell surface localization of full-length Sulf1 and Sulf1ΔHDC, but not in the case of ΔHD or ΔHDB (Fig. 7A), indicating that the HD is responsible for cell surface localization of the enzyme. The basic cluster at the C-terminal end of the HD, which is present in the case of...
The HD Preferentially Binds to Heparan Sulfate at the Cell Surface—As a complementary approach to the cell surface binding experiments using Sulf1 deletion mutants, the ability of the HD alone to interact with the cell surface was investigated. To this end, purified GST-HD was added to untransfected fibroblasts and detected using GST antibodies. Compared with the GST control, a clear cell surface association was seen for GST-HD (Fig. 7B). This binding could also be detected and quantified in FACS experiments, again using an antibody directed against the GST tag (Fig. 7C). At identical protein concentrations, the largest shift in fluorescence intensities was observed for GST-HDC, whereas GST-HDB, lacking the basic domain, did not interact with the chip surface. Using the BLAevaluation software, the binding curves of GST-HD were fitted to determine dissociation constants and kinetic parameters. The best fit was obtained using the heterogeneous ligand model, corresponding to the heterogeneity of the heparin chains ($\chi^2 = 0.046$, i.e. <0.2% of the maximum response signal $R_{max}$). This model is based on the assumption of two independent binding sites, a high affinity and a low affinity site. Although binding of the HD might be even more complex due to the structural variability of heparin and especially HS, the nanomolar dissociation constants $K_{D1} = 0.6 \text{nm}$ ($k_{on1} = 1.4 \times 10^5 \text{M}^{-1} \text{s}^{-1}$, $k_{off1} = 8.4 \times 10^{-5} \text{s}^{-1}$) and $K_{D2} = 17 \text{nm}$ ($k_{on2} = 1.2 \times 10^4 \text{M}^{-1} \text{s}^{-1}$, $k_{off2} = 2.1 \times 10^{-4} \text{s}^{-1}$) underline that the HD mediates high affinity binding toward heparin and the S-domains of HSPGs.

DISCUSSION

Editing of 6O-sulfation of cell surface HSPGs represents a novel mechanism by which the signal transduction pathways of various growth factors and morphogens can be modulated. How the two endosulfatases Sulf1 and Sulf2 recognize their HS substrates and how membrane targeting is achieved are critical questions for understanding their function in cell signaling processes. The present study demonstrates that the HD and distinct regions thereof have important functions in mediating high affinity GAG binding and enzyme activity.

The HD Is a Novel Heparin/HS-binding Domain That Interacts in a 6O-Sulfate-dependent Manner—Deletion of the HD of Sulf1 strongly reduces the cell surface localization of Sulf1 and leads to increased secretion of the enzyme into the medium.
Taken together, the results from the deletion mutants underline that the HD and especially the outer regions are essential for cell surface targeting. For direct or indirect attachment to the cell membrane, several potential interaction partners have to be considered, including different classes of proteoglycans, other proteins, and also negatively charged phospholipids. As shown by FACS experiments with heparinase-treated fibroblasts, the HD of human Sulf1 preferentially binds to heparan sulfate chains, indicating that the HD mediates interactions with the HS chains of HSPGs, the substrate of Sulf1 and Sulf2. These findings contradict previous reports on QSulf1, which had either excluded HS as an interaction partner (5) or assumed non-selective binding of the HD to negatively charged GAGs (30).

To compare the heparin/HS binding properties of the HD with other GAG-binding proteins, heparin affinity chromatography was employed, using immobilized heparin as a matrix and gradient elution with increasing concentrations of NaCl. In previous studies, typical heparin-binding proteins, such as thrombin, antithrombin III, and heparin cofactor II, exhibited elution peaks at 470, 760, or 220 mM NaCl, respectively (40). In contrast, binding of GST-HD was significantly stronger with elution peaks at >1000 mM NaCl, similar to the affinity of FGF1 (41). Combined with the data from surface plasmon resonance experiments, indicating stable complex formation between the HD and heparin with nanomolar affinity, these results imply that the HD represents a novel high affinity heparin/HS-binding domain that localizes the enzyme close to the 6O-sulfate substrate groups.

Yet, the Sulfs also need to be released from their substrate to fulfill their function at the cell surface. We could show that the binding of GST-HD to HS was almost completely abrogated after treatment of HS with enzymatically active
Sulf1ΔHD C. This result indicates that the binding of GST-HD specifically depends on the 6-O-sulfated substrate disaccharides, i.e. UA(2S)-GlcNS(6S) and UA-GlcNS(6S) (24), and that dissociation and mobility of Sulf1 are promoted by substrate turnover. This would allow the enzyme to reach other proteoglycan substrates at the cell surface and also in the extracellular matrix.

Due to the large size of the HD, it seems likely that multiple contacts to adjacent or more distant sites are required for a stable interaction with heparin/HS. Based on the analysis of the different deletion mutants, the inner region of the HD, encoded by the less conserved exons 13 and 14, appears not to be involved in GAG binding. As seen for Sulf1ΔHDC, the loss of the inner region does not affect the cell surface localization. Consistent with these data, the GST-HDC fusion protein exhibited high affinity toward heparan sulfate, heparin, and mammalian cell surfaces. Compared with GST-HD, the increased affinity of GST-HDC toward heparin and especially HS might be explained by a hypothetical model in which the N- and C-terminal regions of the HD contain at least two independent GAG-binding sites, which come into close contact upon deletion of the HD inner region. This proximity could allow binding of the protein within the same S-domain of HS, whereas the presence of the inner region in GST-HD might result in orientation of the binding sites where only one site can interact with one S-domain (Fig. 8). This model would also explain why the observed differences in binding efficiencies were less prominent with homogeneously sulfated heparin as the binding partner. In the case of full-length Sulf1, the inner region might have structural importance to regulate HS affinity or to enable “tandem” interactions of the HD outer regions with two different GAG chains simultaneously.

Biochemical Properties of Sulf1 with and without HD—Using different Sulf1 deletion mutants, the role of the HD in enzymatic activity was investigated. Enzyme assays with the physiological substrate, HS, as well as with the pseudosubstrate 4-MUS demonstrate that the HD of Sulf1 is required for enzyme function, corresponding to previous reports on QSulf2 (30). A deletion of the inner region of the HD does not affect activity or substrate specificity toward HS or 4-MUS. In contrast, the loss of the entire HD leads to a reduced activity toward 4-MUS, whereas activity is completely lost against HS, supporting recent results also from Sulf2 (31). Taken together, these findings support a model in which the HS chain is first bound by the HD to neutralize its negative charge and then presented to the active site for efficient catalysis (30). The small pseudosubstrate 4-MUS might simply diffuse into the active site and thus does not require the presence of the HD. In this context, the sulfate-induced activation of Sulf1ΔHDC toward 4-MUS, but not toward HS as a substrate, might indicate that the sulfate ions are able to occupy binding sites within the HD, mimicking the HS chain and leading to neutralization of the positive charge and subsequent conformational changes. Also the basic cluster at the C-terminal end of the HD appears to be essential for Sulf1 activity, as deletion of this cluster represents the only difference between Sulf1ΔH (inactive) and Sulf1ΔHDB (active). Finally, it was shown for the first time that deletion of large parts of the HD does not alter HS substrate specificity of Sulf1. In both active mutants Sulf1ΔHDB and Sulf1ΔHDC, the trisulfated UA(2S)-GlcNS(6S) unit was the preferred substrate group within HS chains, confirming that the selection of specific positions is mediated by the active site rather than by the HD.

Perspectives—Based on its high activity in vitro and significantly increased secretion, the Sulf1ΔHDC variant allowed the biochemical and kinetic characterization of heparin and heparan sulfate desulfation. Furthermore, this mutant opens up new possibilities to obtain larger amounts of functional enzyme, which will be useful for further applications such as cell culture-based assays, also in comparison to Sulf2 (12). The general applicability of Sulf1ΔHDC has been demonstrated by the reduction of the FGF signaling response after incubation of Sulf1/Sulf2 double-deficient mouse embryonic fibroblasts with Sulf1ΔHDC. This assay suggests that the purified protein will be helpful to study also other growth factor signaling pathways dependent on heparan sulfate 6-O-sulfate groups. Interestingly, it has recently been shown that deletion of the furin cleavage sites within the HD of Sulf1 and Sulf2 renders both enzymes unable to activate Wnt signaling (31). This finding was attributed to the reduced localization of the uncleavable Sulf mutants into lipid rafts. In contrast to Wnt signaling, we show here that Sulf1ΔHDC, a mutant lacking both furin cleavage sites due to the deletion of the inner region of the HD, is able to modulate FGF2 signal transduction. This difference is likely due to the
The Hydrophilic Domain of Human Sulf1

highly soluble nature of exogenous Sulf1 ΔHDC, which might allow the enzyme to freely access raft and non-raft located proteoglycans on the cell surface. In addition to its ability to modulate cell signaling, Sulf1 ΔHDC will serve as an important tool for further research investigating the role of 6-O-sulfate groups. 6-O-Desulfated HS material, generated by Sulf1 ΔHDC treatment, can be used for example, in surface plasmon resonance studies to explicitly investigate the role of substrate sulfates in binding of the HD. Protein crystallography of the isolated HD in complex with defined HS oligosaccharides will help to further understand the role of the HD with regard to substrate recognition and enzyme mechanism. Moreover, structural analysis of the HD will also contribute to a more detailed understanding of how the analog code of HS sulfation is recognized and deciphered by proteins at the molecular level.

Acknowledgments—We thank Katrin Wollschläger for help with surface plasmon resonance experiments, valuable discussions, and critically reading the manuscript. We thank Norbert Sewald for provision of the Biacore 3000 system.

REFERENCES

1. Diersks, T., Schmidt, B., Borissenko, I. V., Peng, J., Preusser, A., Mariappan, M., and von Figura, K. (2003) Cell 113, 435–444
2. Cosma, M. P., Pepe, S., Annunziata, I., Newbold, R. F., Grome, M., Parenti, G., and Ballabio, A. (2003) Cell 113, 445–456
3. Diersks, T., Schlotawa, L., Frese, M. A., Radhakrishnan, K., von Figura, K., and Schmidt, B. (2009) Biochim. Biophys. Acta Mol. Cell Res. 1793, 710–725
4. Diez-Roux, G., and Ballabio, A. (2005) Annu. Rev. Genomics Hum. Genet. 6, 355–379
5. Dhoot, G. K., Gustafsson, M. K., Ai, X., Sun, W., Standiford, D. M., and Emerson, C. P., Jr. (2001) Science 293, 1663–1666
6. Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S., and Diersks, T. (2002) J. Biol. Chem. 277, 49175–49183
7. Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) Annu. Rev. Biochem. 68, 729–777
8. Saisiekharan, R., Ramam, R., and Prabhakar, V. (2006) Annu. Rev. Biomed. Eng. 8, 181–231
9. Ai, X., Do, A. T., Lozynska, O., Kusche-Gullberg, M., Lindahl, U., and Emerson, C. P., Jr. (2003) J. Cell Biol. 162, 341–351
10. Viviano, B. L., Paine-Saunders, S., Giusaniñas, N., Gallagher, J., and Saunders, S. (2004) J. Biol. Chem. 279, 5604–5611
11. Wang, S., Ai, X., Freeman, S. D., Pownall, M. E., Lu, Q., Kessler, D. S., and Emerson, C. P., Jr. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 4833–4838
12. Uchimura, K., Morimoto-Tomita, M., Bistrop, A., Li, J., Lyon, M., Gallagher, J., Werb, Z., and Rosen, S. D. (2006) BMC Biochem. 7, 2
13. Nawroth, R., van Zante, A., Cervantes, S., McManus, M., Hebrot, M., and Rosen, S. D. (2007) PLoS ONE 2, e92
14. Morimoto-Tomita, M., Uchimura, K., Bistrop, A., Lum, D. H., Egeblad, M., Boudreau, N., Werb, Z., and Rosen, S. D. (2005) Neoplasia 7, 1001–1010
15. Narita, K., Staub, J., Chien, J., Meyer, K., Bauer, M., Friedl, A., Ramakrishnan, S., and Shridhar, V. (2006) Cancer Res. 66, 6025–6032
16. Lai, J., Chien, J., Staub, J., Avula, R., Greene, E. L., Matthews, T. A., Smith, D. I., Kaufmann, S. H., Roberts, L. R., and Shridhar, V. (2003) J. Biol. Chem. 278, 23107–23117
17. Lamanna, W. C., Baldwin, R. J., Padva, M., Kalus, I., Ten Dam, G., van Kuppevelt, T. H., Gallagher, J. T., von Figura, K., Diersks, T., and Merry, C. L. (2006) Biochem. J. 400, 63–73
18. Ai, X., Kitazawa, T., Do, A. T., Kusche-Gullberg, M., Labosky, P. A., and Emerson, C. P., Jr. (2007) Development 134, 3327–3338
19. Holst, C. R., Bou-Reslan, H., Gore, B. B., Wong, K., Grant, D., Chalasani, S., Carano, R. A., Frantz, G. D., Tessier-Lavigne, M., Bolon, B., French, D. M., and Ashkenazi, A. (2007) PLoS ONE 2, e575
20. Lum, D. H., Tan, J., Rosen, S. D., and Werb, Z. (2007) Mol. Cell. Biol. 27, 678–688
21. Lamanna, W. C., Kalus, I., Padva, M., Baldwin, R. J., Merry, C. L., and Diersks, T. (2007) J. Biotechnol. 129, 290–307
22. Kalus, I., Salmen, B., Viebahn, C., von Figura, K., Schmitz, D., D’Hoore, R., and Diersks, T. (2009) J. Cell. Mol. Med. in press, DOI 10.1111/j.1582-4934.2008.00558.x
23. Ratza, A., Kalus, I., Moser, M., Diersks, T., Mundlos, S., and Vortkamp, A. (2008) Dev. Dyn. 237, 339–353
24. Lamanna, W. C., Frese, M. A., Balleininger, M., and Diersks, T. (2008) J. Biol. Chem. 283, 27724–27735
25. Li, W., Johnson, D. J., Esmon, C. T., and Huntington, J. A. (2004) Nat. Struct. Mol. Biol. 11, 857–862
26. Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., and Blundell, T. L. (2000) Nature 407, 1029–1034
27. Cardin, A. D., and Weintraub, H. J. (1989) Arteriosclerosis 9, 21–32
28. Sobel, M., Soler, D. F., Kermode, J. C., and Harris, R. B. (1992) J. Biol. Chem. 267, 8857–8862
29. Hileman, R. E., Fromm, J. R., Weiler, J. M., and Linhardt, R. J. (1998) BioEssays 20, 156–167
30. Ai, X., Do, A. T., Kusche-Gullberg, M., Lindahl, U., Lu, K., and Emerson, C. P., Jr. (2006) J. Biol. Chem. 281, 4969–4976
31. Tang, R., and Rosen, S. D. (2009) J. Biol. Chem. 284, 21505–21514
32. Melcher, K. (2000) Anal. Biochem. 277, 109–120
33. Frese, M. A., Schulz, S., and Diersks, T. (2008) J. Biol. Chem. 283, 11388–11395
34. Preusser-Kunze, A., Mariappan, M., Schmidt, B., Gande, S. L., Mutenda, K., Wenzel, D., von Figura, K., and Diersks, T. (2005) J. Biol. Chem. 280, 14900–14910
35. Osmond, R. I., Kett, W. C., Skett, S. E., and Coombe, D. R. (2002) Anal. Biochem. 310, 199–207
36. Lundquist, P., Märtensson, J., Sörbo, O., and Ohman, S. (1980) Clin. Chem. 26, 1178–1181
37. Merry, C. L., Bullock, S. D., Swain, D. C., Backen, A. C., Lyon, M., Beddington, R. R., Wilson, V. A., and Gallagher, I. J. (2001) J. Biol. Chem. 276, 35429–35434
38. Ambasta, R. K., Ai, X., and Emerson, C. P., Jr. (2007) J. Biol. Chem. 282, 34492–34499
39. Eisenthal, R., and Cornish-Bowden, A. (1974) Biochem. J. 139, 715–720
40. Eckert, R., and Ragg, H. (2003) FEBS Lett. 541, 121–125
41. Klagsbrun, M. (1990) Curr. Opin. Cell Biol. 2, 857–863